| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 |
Form 4: Wang Xiaodong, Director
Gave 1,183 shares as a gift |
| 10 Nov 2026 |
Form 4: Ball Titus B., Principal Accounting Officer
Received 1,559 shares by exercise or conversion ($291K) · Sold 1,559 shares ($632K) |
| 09 Nov 2026 |
Form 4: Lee Chan Henry, SVP, General Counsel
Sold 1,115 shares ($447K) |
| 06 Nov 2026 | 144 |
| 05 Nov 2026 | 144 |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
SAN CARLOS, Calif. – November 5, 2026 – BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026. |
| 29 Oct 2026 |
Form 4: Wang Xiaodong, Director
Received 31,028 shares by exercise or conversion ($1.14M) · Sold 31,028 shares ($11.3M) |
| 15 Oct 2026 |
Form 4: Wang Xiaodong, Director
Received 31,027 shares by exercise or conversion ($1.14M) · Sold 31,027 shares ($10.9M) |
| 02 Oct 2026 |
Form 4: Lee Chan Henry, SVP, General Counsel
Sold 1,115 shares ($418K) |
| 30 Sep 2026 |
Form 4: Wang Xiaodong, Director
Received 31,028 shares by exercise or conversion ($1.14M) · Sold 31,028 shares ($11.3M) |
| 30 Sep 2026 | 144 |
| 16 Sep 2026 | SCHEDULE 13D/A |
| 16 Sep 2026 |
Form 4: Baker Bros. Advisors Lp, Director and 5 others
Received 61,536 shares by exercise or conversion ($2.27M) |
| 10 Sep 2026 |
Form 4: Wang Xiaodong, Director
Sold 38,287 shares ($13.4M) · Received 31,027 shares by exercise or conversion ($1.14M) |
| 08 Sep 2026 | 144 |
| 03 Sep 2026 |
Form 4: Ball Titus B., Principal Accounting Officer
Sold 132 shares ($47K) |
| 01 Sep 2026 | 144 |
| 27 Aug 2026 |
Form 4: Wu Xiaobin, President and COO
Sold 280 shares ($106K) |
Loading...